Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that BRAF p.V600K status confers therapeutic sensitivity to Binimetinib, Encorafenib in patients with Melanoma.
The European Medicines Agency (EMA) has authorized binimetinib in combination with encorafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
This statement is based on a regulatory approval from the European Medicines Agency:
Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.